达格列净应用于血糖控制未达标的2型糖尿病患者的效果分析

Analysis of the Effect of Dapagliflozin Application in Patients with Type 2 Diabetes Mellitus with Substandard Blood Glucose Control

目的:分析达格列净应用于血糖控制未达标的2型糖尿病患者的效果。方法:选取2022年10月—2023年8月海淀区北坞嘉园社区卫生服务站收治的血糖控制未达标的2型糖尿病患者300例作为研究对象,采用随机数字表法分为对照组与研究组,各150例。对照组接受常规降糖药治疗,研究组在对照组基础上给予达格列净。比较两组治疗效果。结果:治疗后,两组空腹胰岛素、餐后2 h胰岛素水平高于治疗前,且研究组高于对照组,两组空腹血糖、餐后2 h血糖水平低于对照组,且研究组低于对照组,差异有统计学意义(P<0.05)。治疗后,两组血清总胆固醇、甘油三酯、低密度蛋白胆固醇水平低于治疗前,且研究组低于对照组,两组高密度脂蛋白胆固醇水平高于治疗前,且研究组高于对照组,差异有统计学意义(P<0.05)。研究组不良反应总发生率低于对照组,差异有统计学意义(P=0.017)。结论:达格列净应用于血糖控制未达标的2型糖尿病患者的效果显著,能够有效改善胰岛功能,控制血糖、血脂水平,且安全性较高,值得临床应用并予以推广。

Objective:To analyze the effect of dapagliflozin application in patients with type 2 diabetes mellitus with substandard blood glucose control.Methods:Three hundred patients with type 2 diabetes mellitus with substandard blood glucose control admitted to Beijing Haidian District Beiwu Jiayuan Community Health Service Station from October 2022 to August 2023 were selected as the study subjects,and were divided into the control group and the study group using the randomized numerical table method,each with one hundred and fifty cases.The control group was treated with conventional hypoglycemic drugs,and the study group was given dapagliflozin on the basis of the control group.Compare the treatment effect of the two groups.Results:After treatment,the levels of fasting insulin and 2 h postprandial insulin in both groups were higher than those before treatment,and the study group was higher than the control group,and the levels of fasting glucose and 2 h postprandial glucose in both groups were lower than those in the control group,and the study group was lower than the control group,and the difference was statistically significant(P<0.05);after treatment,the serum total cholesterol,triglyceride and LDL cholesterol levels of the two groups were lower than those before treatment,and the study group was lower than the control group,and the HDL cholesterol levels of the two groups were higher than those before treatment,and the study group was higher than the control group,and the difference was statistically significant(P<0.05);the total incidence of adverse reactions in the study group was lower than that in the control group,and the difference was statistically significant(P=0.017).Conclusion:The application of dapagliflozin in patients with type 2 diabetes mellitus with substandard blood glucose control is effective in improving pancreatic islet function,controlling blood glucose and lipid levels,and with high safety,it is worthwhile to be clinically applied and popularized.